12:33 PM EDT, 04/07/2025 (MT Newswires) -- Vertex Pharmaceuticals ( VRTX ) said Monday that the European Commission has expanded the label for Kaftrio in cystic fibrosis to include patients 2 years and older who have at least one non-class I mutation in the cystic fibrosis conductance regulator gene.

The company said around 4,000 cystic fibrosis patients in the European Union are now eligible to receive the medicine.

Kaftrio, or ivacaftor/tezacaftor/elexacaftor, is administered in combination with ivacaftor to treat cystic fibrosis patients.

Vertex said eligible patients in Austria, Denmark, Ireland, Norway, Sweden and Germany are expected to have access to Kaftrio "shortly."

Price: 469.03, Change: -5.59, Percent Change: -1.18